ArticlePloS one2012
Cell cycle gene networks are associated with melanoma prognosis.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Parkinson's Disease is Associated with Dysregulations of a Dopamine-Modulated Gene Network Relevant to Sleep and Affective Neurobehaviors in the Striatum.Scientific reports · 2019Pooled it
- Systematic identification of mutations and copy number alterations associated with cancer patient prognosis.eLife · 2018Pooled it
- Gene Network Rewiring to Study Melanoma Stage Progression and Elements Essential for Driving Melanoma.PloS one · 2015Pooled it
- PredictedInternational journal of molecular sciences · 2026Article
- Inference of drug off-target effects on cellular signaling using interactome-based deep learning.iScience · 2024Article
- Novel cancer subtyping method based on patient-specific gene regulatory network.Scientific reports · 2021Article
- Dynamic changes in gene-to-gene regulatory networks in response to SARS-CoV-2 infection.Scientific reports · 2021Article
- BCL2L10 Is Overexpressed in Melanoma Downstream of STAT3 and Promotes Cisplatin and ABT-737 Resistance.Cancers · 2020Article
- Genomic and transcriptomic landscape of conjunctival melanoma.PLoS genetics · 2020Article
- Computational models of melanoma.Theoretical biology & medical modelling · 2020Review
- System-Based Differential Gene Network Analysis for Characterizing a Sample-Specific Subnetwork.Biomolecules · 2020Article
- Modelling TERT regulation across 19 different cancer types based on the MIPRIP 2.0 gene regulatory network approach.BMC bioinformatics · 2019Article
- Benchmark and integration of resources for the estimation of human transcription factor activities.Genome research · 2019Article
- TCEA1 regulates the proliferative potential of mouse myeloid cells.Experimental cell research · 2018Article
- Standardization of A375 human melanoma models on chicken embryo chorioallantoic membrane and Balb/c nude mice.Oncology reports · 2017Article
- Article
- Underexpression of Specific Interferon Genes Is Associated with Poor Prognosis of Melanoma.PloS one · 2017Article
- Article
- Cross-platform comparison of independent datasets identifies an immune signature associated with improved survival in metastatic melanoma.Oncotarget · 2016Article
- Multiscale Embedded Gene Co-expression Network Analysis.PLoS computational biology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur understanding of the molecular pathways that underlie melanoma remains incomplete. Although several published microarray studies of clinical melanomas have provided valuable information, we found only limited concordance between these studies. Therefore, we took an in vitro functional genomics approach to understand melanoma molecular pathways. METHODOLOGY/PRINCIPAL
findingsAffymetrix microarray data were generated from A375 melanoma cells treated in vitro with siRNAs against 45 transcription factors and signaling molecules. Analysis of this data using unsupervised hierarchical clustering and Bayesian gene networks identified proliferation-association RNA clusters, which were co-ordinately expressed across the A375 cells and also across melanomas from patients. The abundance in metastatic melanomas of these cellular proliferation clusters and their putative upstream regulators was significantly associated with patient prognosis. An 8-gene classifier derived from gene network hub genes correctly classified the prognosis of 23/26 metastatic melanoma patients in a cross-validation study. Unlike the RNA clusters associated with cellular proliferation described above, co-ordinately expressed RNA clusters associated with immune response were clearly identified across melanoma tumours from patients but not across the siRNA-treated A375 cells, in which immune responses are not active. Three uncharacterised genes, which the gene networks predicted to be upstream of apoptosis- or cellular proliferation-associated RNAs, were found to significantly alter apoptosis and cell number when over-expressed in vitro. CONCLUSIONS/SIGNIFICANCE: This analysis identified co-expression of RNAs that encode functionally-related proteins, in particular, proliferation-associated RNA clusters that are linked to melanoma patient prognosis. Our analysis suggests that A375 cells in vitro may be valid models in which to study the gene expression modules that underlie some melanoma biological processes (e.g., proliferation) but not others (e.g., immune response). The gene expression modules identified here, and the RNAs predicted by Bayesian network inference to be upstream of these modules, are potential prognostic biomarkers and drug targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.